The Autonomous University of Querétaro (UAQ) participates in meetings with the Ministry of Foreign Affairs (SRE), through the Mexican Agency for International Development Cooperation (AMEXCID), and the Consortium of Innovative Scientists for the Production of Anti-Vaccines. COVID-19, in which in the near future the Alma Mater of Querétaro will present the results obtained in the preclinical evaluation of its project for a vaccine based on chimeric peptides.
This as part of a follow-up carried out on research projects focused on the development of vaccines, diagnostic methods and pharmacological treatments around COVID-19 that were funded by AMEXCID, in order to know what is being done with it. resource granted and the achievements made from it.
Dr. Juan Joel Mosqueda Gualito, leader of the group of researchers working on the creation of the UAQ anti-SARS CoV-2 vaccine, explained that the University will present the advances generated in the experiments carried out to evaluate the safety, the toxicity and immunogenicity of the antigen and a statement of what is needed to continue its development.
“What they want is to know the progress, because surely when there are projects that can no longer advance further, they will no longer continue to support them, because not all have successful results. We have had very good results and I am very excited to present them, but we are still missing ”, he said.
The researcher announced that in April a semi-annual evaluation of the projects will be carried out, including that of the Maximum House of Studies in Querétaro and, depending on its progress, the SRE will decide whether to continue supporting it financially, for which case the University will present proposals for financing.
« As these are quite expensive clinical stages, surely they will no longer be able to support all the projects they are currently financing and they will have to choose the most advanced or those with the most successful results, » he said.
Dr. Mosqueda Gualito considered that the SRE has shown interest in helping research in relation to the COVID-19 pandemic and solving the problems faced by working groups funded by AMEXCID.
He added that the UAQ has been supporting the donations made by companies and civil society for the development of the vaccine, which means that people have confidence in the project and with which, together with the contributions of the University itself, it seeks purchase new equipment that allows continuity in antigen creation.
At these meetings, Lic. Marcelo Ebrard Casaubon, Secretary of Foreign Relations; Mtra. Martha Delgado, Undersecretary for Multilateral Affairs and Human Rights of the SRE; Dr. Laura Carrillo Cubillas, executive director of AMEXCID; Dr. Esther Orozco, scientific advisor to the SRE and coordinator of the Consortium of Innovative Scientists for the Production of Anti-SARS CoV-2 Vaccines .; and research project leaders.